We are live on ! Find out more

ALDR

Alder Biopharmaceuticals

ALDR

Delisted

ALDR was delisted on the 21st of October, 2019.

124 hedge funds and large institutions have $733M invested in Alder Biopharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 39 increasing their positions, 36 reducing their positions, and 22 closing their positions.

New

Increased

Maintained

Reduced

Closed

8% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 36

3% less funds holding

Funds holding: 128 → 124 (-4)

18% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 22

38% less capital invested

Capital invested by funds: $1.19B → $733M (-$454M)

50% less funds holding in top 10

Funds holding in top 10: 4 → 2 (-2)

62% less call options, than puts

Call options by funds: $253K | Put options by funds: $673K

Holders

124

Holders Change

-4

Holders Change %

-3.13%

% of All Funds

2.76%

Holding in Top 10

Holding in Top 10 Change

-2

Holding in Top 10 Change %

-50%

% of All Funds

0.04%

New

Increased

Reduced

Closed

Calls

$253K

Puts

$673K

Net Calls

-$420K

Net Calls Change

+$2.28M

Top Buyers

Rank	Fund	Capital Flow
1	Goldman Sachs New York	+$20.1M
2	SC Samlyn Capital New York	+$11.6M
3	Wellington Management Group Boston, Massachusetts	+$8M
4	BB BB Biotech Schaffhausen, Switzerland	+$6.4M
5	T. Rowe Price Associates Baltimore, Maryland	+$6.27M

Top Sellers

Rank	Fund	Capital Flow
1	PHS PFM Health Sciences San Francisco, California	-$31.9M
2	FCMI Foresite Capital Management IV Larkspur, California	-$16.7M
3	Man Group London, United Kingdom	-$8.55M
4	SAM Sectoral Asset Management Montreal, Quebec, Canada	-$6.16M
5	Fidelity Investments Boston, Massachusetts	-$6.07M

#	Name	Holding	Trade Value	Shares Change	Change in Stake
26	26 Northern Trust Chicago, Illinois	$7.19M	-$115K	-8,973	-1%
27	27 Geode Capital Management Boston, Massachusetts	$6.65M	+$375K	+29,296	+5%
28	LPC 28 Lion Point Capital New York	$5.96M	–	–	–
29	29 Millennium Management New York	$4.89M	+$3.83M	+299,538	+168%
30	30 Point72 Asset Management Stamford, Connecticut	$4.62M	+$5.77M	+450,500	New
31	DCM 31 DAFNA Capital Management Los Angeles, California	$4.06M	–	–	–
32	SSA 32 Schonfeld Strategic Advisors New York	$3.81M	+$230K	+18,000	+5%
33	33 Citigroup New York	$3.4M	+$2.56M	+200,294	+152%
34	34 Charles Schwab San Francisco, California	$3.33M	-$32.9K	-2,566	-0.8%
35	35 Deutsche Bank Frankfurt Am Main Ge, Germany	$2.76M	-$941K	-73,492	-21%
36	36 Bank of New York Mellon New York	$2.72M	-$17.3K	-1,351	-0.5%
37	37 JP Morgan Chase New York	$2.63M	-$182K	-14,232	-5%
38	38 AllianceBernstein Nashville, Tennessee	$2.6M	+$1.92M	+150,000	+145%
39	CS 39 Candriam SCA Strassen, Luxembourg, Luxembourg	$2.33M	–	–	–
40	40 TD Asset Management Toronto, Ontario, Canada	$2.17M	+$198K	+15,488	+8%
41	AG 41 Artal Group Luxembourg	$2.05M	+$2.56M	+200,000	New
42	FI 42 Fosun International Hong Kong, China	$1.89M	+$320K	+25,000	+16%
43	43 American Century Companies Kansas City, Missouri	$1.57M	-$238K	-18,589	-11%
44	TA 44 Teachers Advisors New York	$1.32M	+$111K	+8,701	+7%
45	SAM 45 Sectoral Asset Management Montreal, Quebec, Canada	$1.31M	-$6.16M	-481,312	-79%
46	46 Norges Bank Oslo, Norway	$1.2M	–	–	–
47	47 Wells Fargo San Francisco, California	$1.17M	-$850K	-66,413	-37%
48	48 Swiss National Bank Zurich, Switzerland	$1.12M	–	–	–
49	MOACM 49 Mutual of America Capital Management New York	$1.11M	–	–	–
50	50 D.E. Shaw & Co New York	$1.04M	+$1.11M	+86,390	+554%

ALDR Hedge Fund Activity: Q4 2018 in Review

124 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Alder Biopharmaceuticals (ALDR) for Q4 2018, worth a combined $733M — down 38% from $1.19B a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of ALDR and 18 opened new positions — a net loss of 4 holders — while 36 trimmed existing stakes and 39 added.

The largest buyer was Goldman Sachs, adding an estimated $20.1M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $31.9M sold.

124 institutional investors held Alder Biopharmaceuticals (ALDR) as of Q4 2018, down from 128 in Q3 2018.
Funds reported $733M of Alder Biopharmaceuticals stock for Q4 2018, down 38% quarter-over-quarter.
18 funds opened new Alder Biopharmaceuticals positions in Q4 2018 and 22 closed out, a net change of -4 holders.
The largest Alder Biopharmaceuticals buyer in Q4 2018 was Goldman Sachs, an estimated $20.1M added.
The largest Alder Biopharmaceuticals seller in Q4 2018 was PFM Health Sciences, an estimated $31.9M sold.

Based on aggregated 13F filings for Q4 2018.

Alder Biopharmaceuticals ALDR